Cortexyme to Present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021

Rhea-AI Summary

Cortexyme, Inc. (Nasdaq: CRTX) announced that Chris Lowe, COO and CFO, will present at the Oppenheimer 31^st Annual Healthcare Conference on March 16, 2021, at 4:00 p.m. EDT. This virtual event will include a live webcast available on Cortexyme's Investor Calendar page, where it will remain accessible for 90 days. Cortexyme is focused on developing treatments for Alzheimer’s and other degenerative diseases, with its lead candidate, atuzaginstat (COR388), currently in the GAIN Trial, a Phase 2/3 study targeting a specific pathogen associated with degeneration.

Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today announced Chris Lowe, the company’s chief operating officer and chief financial officer, will present at the Oppenheimer 31^st Annual Healthcare Conference, a virtual event, on Tuesday, March 16, 2021, at 4:00 p.m. EDT / 1:00 p.m. PDT.

A live webcast of the presentation will be accessible on the Investor Calendar page under the News & Events heading of the Cortexyme investor site (ir.cortexyme.com). The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005461/en/

FAQ

When is Cortexyme's presentation at the Oppenheimer 31st Annual Healthcare Conference?

Cortexyme's presentation is scheduled for March 16, 2021, at 4:00 p.m. EDT.

Who will present for Cortexyme at the Oppenheimer Conference?

Chris Lowe, the COO and CFO of Cortexyme, will present.

How can I access the live webcast of Cortexyme's presentation?

The live webcast can be accessed on the Investor Calendar page of Cortexyme's investor site.

What is the focus of Cortexyme, Inc.?

Cortexyme is focused on developing therapies for Alzheimer’s and other degenerative diseases.

What is Cortexyme's lead therapeutic candidate?

Cortexyme's lead candidate is atuzaginstat (COR388), currently in the GAIN Trial.

What is the GAIN Trial?

The GAIN Trial is an ongoing Phase 2/3 clinical trial for patients with mild to moderate Alzheimer’s disease.